Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.
Daneng Li(City Of Hope National Medical Center), Grey Wilkinson, Paul Woodard, Patrick M. Travis(Highlands Oncology Group), Jennifer L. Leddon(University of Cincinnati), Anthony F. Shields(Wayne State University), Amanda Seiz(South Texas Accelerated Research Therapeutics), Stanley R. Hamilton(City of Hope), Colt A. Egelston(City Of Hope National Medical Center), John Byon, Janet Austria(City Of Hope National Medical Center), Hirva Mamdani(Wayne State University), Oscar Colunga Flores(City Of Hope National Medical Center), Sharon Yavrom
Cited by 2
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
|Science|1989|2.1k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Mutation of a <i>mutL</i> Homolog in Hereditary Colon Cancer
|Science|1994|1.8k